PCI Biotech har meget dyktig ansatte, ledelse, styret og advisory board. Ti av ti mulig poeng! Vel utført jobb, keep up the good work.
Når det gjelder PCI Biotech sitt nye styremedlem fra Mai 2018 mister Hughes er det meget interessant at bakgrunnen er internasjonal i BP og ikke minst flere solide stillinger i AstraZeneca!!!
Er det slik at dette er AZ sin mann i styret indirekte? Har AZ gjort sin solide due dilligence i alle ledd i PCI Biotech? Teknologien, styret, ledelse mm. Check, check and go for a PCIB deal?
Board Member Professor Andrew Hughes, MD, PhD
Professor Hughes holds an MD from Cambridge, UK, and a PhD degree in behavioural neuroendocrinology. After practicing general clinical medicine in Manchester’s teaching hospitals, he joined Zeneca in 1994. He had roles of growing managerial responsibility in AstraZeneca, including Worldwide Director of Discovery Medicine; Oncology and Infection, Worldwide Clinical Head of Early Phase Oncology, and most recently Global VP of Early Clinical Development. He has been clinical investigator on over 200 clinical trials and leading over 50 research and early clinical development programmes of novel candidate drugs. Currently Professor Hughes holds a position as Strategy Director of the experimental cancer medicine at Manchester Cancer Research Centre, UK. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He became a Board member of PCI Biotech Holding ASA in May 2018.
